|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In contrast, the expression of the c-neu and the c-myc genes at the protein level had no influence on the take rate of the tumors in nude mice.
|
8297109 |
1994 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Human adenocarcinomas commonly harbor mutations in the KRAS and MYC proto-oncogenes and the TP53 tumor suppressor gene.
|
16878133 |
2006 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
MYC amplification was the most common alteration, present in 75% of tumors.
|
27397723 |
2016 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The cases with DNA available were evaluated for MYC rearrangement (MYC-R) by Southern hybridization of EcoRI-digested tumor DNA using an exon-1 probe, a combination of probe and enzyme known to detect over 85% of breaks in sporadic Burkitt's lymphoma.
|
1671647 |
1991 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In this article, we report a case of an adolescent patient who presented with high-grade breast lymphoma with concurrent BCL2-IGH and MYC-IGL translocations, and we review the clinical, pathological, and genetic features; management strategies; and outcomes associated with this unusual neoplasm.
|
21491965 |
2012 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Increase in copy numbers of MYC detected by FISH was noted in 25% of tumors that had shown 8q gains by CGH and in five cases with no chromosome abnormalities noted by CGH.
|
11257209 |
2001 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We used dual-color fluorescence in situ hybridization (FISH) to characterize the breakpoint locations of chromosomal translocations/rearrangements involving the MYC locus at 8q24 found in a panel of 14 MM cell lines and 70 primary tumors (66 MM and 4 PCL).
|
12759924 |
2003 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Forty-nine tagging SNPs including three previously reported significant variants (rs1447295, rs6983267, rs16901979) and seven variants in the 5' upstream region of the MYC proto-oncogene were tested for association with susceptibility to PC and tumor aggressiveness in 596 histologically verified PC cases and 567 ethnically matched controls.
|
19562729 |
2009 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
MEN-1 gene, although found in some sporadic tumors, is more likely associated with familial adenoma. p53, Ras, Rb, nm23 and c-myc genes play some role in the promotion of tumors especially toward their aggressive variant. p53 gene, which is found in up to 60% of ACTH producing adenomas, through action of p21 inhibits progression of cell cycle from G1 to S phase, by inhibiting the action of cyclin D3 on cdk4.
|
10481784 |
1999 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In combination with p53 silencing, KRAS(G12V) alone was sufficient to fully transform the immortalized HPDECs, and MYC markedly accelerated the development of tumors.
|
24858378 |
2014 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The development of a lung cancer requires multiple genetic changes, consisting of the activation of oncogenes, including the K-ras and myc genes, and of inactivation of tumour suppressor genes, including the Rb, p53 and CDKN2 genes.
|
9441131 |
1997 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Double-hit lymphomas (DHL) with chromosomal rearrangements affecting the avian myelocytomatosis viral oncogene homolog (cMYC) and either the B-cell lymphoma-2 (BCL2) or -6 (BCL6) locus are uncommon neoplasms with an aggressive clinical course and dismal prognosis.
|
24222112 |
2013 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In vivo knockout of ID3 potentiated the effects of MYC, leading to rapid tumorigenesis and tumor phenotypes consistent with those observed in the human disease.
|
31558468 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Interestingly, the highest percentages of PD-L1-positive TCs with the three antibodies were found in samples with cyclin-dependent kinase 6 (CDK6) amplification, with high amplification of proto-oncogene C-Myc (CMYC) or with cyclin D1-PI3 kinase subunit alpha (CCND1-PIK3CA) co-amplification.
|
28815764 |
2018 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Large B-cell lymphomas with IGH@BCL2 and MYC rearrangement, known as double-hit lymphoma (DHL), are clinically aggressive neoplasms with a poor prognosis.
|
25103070 |
2015 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Further analysis on 2 tumors revealed unfavorable histology with MYC protein overexpression but with neither MYCN amplification nor MYCN protein overexpression.
|
29426276 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Thirty-eight (14.6%) of the tumors showed c-myc gene amplification (defined as two or more additional copies of c-myc gene in relation to the number of chromosome 8 centromere).
|
11598174 |
2001 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Burkitt lymphoma arising from lymphoplasmacytic lymphoma following acquisition of MYC translocation and loss of the ETV6 tumor suppressor gene.
|
23276184 |
2013 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Copy number alterations target multiple tumour suppressive/oncogenic loci; however, amplification of MYC is uniquely associated with poor outcome and adenosquamous subtype.
|
25855536 |
2015 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We recently identified a subgroup of TNBC with loss of the tumor suppressor PTEN and five specific microRNAs that exhibits exceedingly poor clinical outcome and contains TP53 mutation, RB1 loss and high MYC and WNT signalling.
|
31836816 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Alterations of the MYC gene were associated with advanced tumor stage.
|
16523260 |
2006 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
NKX3.1 loss was associated with tumor stage (p<0.03) and MYC gain with Gleason score (p<0.03).
|
16310933 |
2006 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We had delineated three subgroups of tumors showing distinct DNA amplification profiles and clinicopathological characteristics: group A, tumors showing amplification at 11q13 and/or 8p12 and/or 20q13; group B, tumors amplified at ERBB2 and/or MYC and/or MDM2/SAS; and group C, tumors with no detectable amplification.
|
9331100 |
1997 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In addition, the tumour sample of the patient was positive for the classical somatic chromosomal translocation t(8;14) involving the c-MYC gene frequently identified in BL.
|
30569626 |
2019 |